Myeloablative doses of BU and fludarabine followed by allogeneic hematopoietic cell transplantation offer effective therapy for AML. We anticipated that pharmacokinetic targeting of i.v. BU to 5300 lM/L min/day Â 4 (targeted i.v. BU and fludarabine (t-i.v. BU/Flu)) would limit nonrelapse mortality (NRM) in adults up to 70 years of age. We assessed the safety and efficacy of t-i.v. BU/ Flu in a series of 100 adults (median age 48, range 22-69 years) with AML in the first CR (CR1) with high risk of treatment failure (n ¼ 49), second CR (CR2, n ¼ 25), relapsed disease (REL, n ¼ 9), primary induction failure (PIF, n ¼ 16) and untreated (n ¼ 1). NRM was 3% at 100 days and 15% at 1 year. The cumulative incidence of relapse was 30.6% for CR1, 41.7% for CR2, 55.6% for REL and 58.6% for PIF. OS for primary AML in CR1 was 66% (95% confidence interval (CI): 46-80%) at 1 year, and 62% (95% CI: 42-77%) at 2 years. On multivariable modeling, remission status, moderate/severe chronic GVHD and day-90 BM chimerism X90% predicted improved OS. Importantly, there was no effect of age. t-i.v. BU/Flu provides effective disease control with encouraging NRM in patients up to age of 70 years.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is the optimal post-remission treatment for intermediate or high risk AML in first remission, and beyond first remission. 1, 2 However, myeloablative conditioning with CY and TBI or BU threatens treatment-related morbidity and mortality, which is prohibitive in older adults. 3, 4 As the median age of AML at diagnosis is 68 years, an array of conditioning strategies has been developed with reduced toxicity. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Available literature suggests that reduced-intensity conditioning followed by allogeneic HCT promises to limit treatment-related mortality, but is complicated by increased risk of primary disease relapse. 6, 11, [18] [19] [20] Oral bioavailability of BU shows large interindividual variation. 21 Increased BU AUC correlates with toxicity including veno-occlusive disease and seizure, [22] [23] [24] and suboptimal BU AUC predicts rejection and disease relapse. 25, 26 Aberrant CY metabolism leads to increased nonrelapse mortality (NRM) and reduced OS. 27 Alternatively, fludarabine offers comparable immunosuppression with low nonhematopoietic toxicity, and evidence to date suggests that a regimen of targeted oral 14 or i.v. BU, 13, 28 combined with fludarabine is effective in the treatment of myeloid malignancies with low toxicity. Several retrospective studies support reduced toxicity and comparable efficacy of i.v. BU and fludarabine (i.v. BU/Flu) compared with historical outcomes with BU and CY. [29] [30] [31] We report retrospective analysis of a consecutive series of adults with AML conditioned with a regimen of pharmacokinetically targeted i.v. BU/Flu (t-iv BU/Flu).
Methods

Patients
In total, 100 consecutive adult AML patients treated with t-i.v. BU/Flu at Moffitt Cancer Center since 2004 with a minimum follow-up of 1 year were identified by retrospective review of patient records. All patients provided informed consent for follow-up of transplant outcome data. The reporting of this data was approved by the University of South Florida Institutional Review Board. Patient characteristics are summarized in Table 1 .
Conditioning, GVHD prophylaxis and supportive care
The conditioning regimen in all cases consisted of fludarabine, 40 mg/m 2 infused over 30 min on days À6 to À3, followed by i. . BU pharmacokinetic samples were obtained on day -6 and analyzed by mass spectrometry; on days À4 and À3, the BU dose was adjusted to target an average AUC of 5300 ( þ /À10%) mmol min (n ¼ 96) or 3500 ( þ /À10%) mmol min (n ¼ 4) for each of the 4 days; the reduced BU target AUC was selected according to transplant physician discretion in four cases because of patient age at transplant (range 62-67 years). Candidacy was determined by standard eligibility criteria for allogeneic HCT (cardiac ejection fraction X45%; FEV1, FVC, DLCO all X50% predicted values; liver function tests o3 times upper limit of normal range; creatinine clearance 450 mL/min; no active infection; human immunodeficiency virus negative; and Karnofsky performance status X60%). GVHD prophylaxis was tacrolimus (TAC)/MTX, except in those patients enrolled in a prospective trial of TAC/MTX vs TAC/MMF acute (aGVHD) prophylaxis at the center during this time frame. One patient received TAC/SIR according to the primary transplant physician's discretion. In all, 20 of 24 total HCT recipients with mismatched unrelated donors received antithymocyte globulin (ATG) in addition to standard aGVHD prophylaxis. None with completely matched unrelated donors received ATG. Standard infectious prophylaxis and viral monitoring was provided to all patients post transplant per institutional guidelines.
Outcomes
Neutrophil engraftment was defined by the first of three successive days with an ANC of 4500 per ml. Platelet engraftment was defined by the first of three successive days with a nontransfused platelet count of 420 000 per ml. Primary graft failure was defined as failure to achieve a neutrophil count of X500 per ml in patients who survive X28 days following transplantation and who have not undergone a second transplant procedure. Secondary graft failure was defined as a decline of neutrophils to o500 per ml after having engrafted that is unresponsive to growth factors and unrelated to effects of medications or infection. The aGVHD was scored as per modified Glucksberg criteria. 33 Chronic GVHD (cGVHD) was scored as per the National Institute of Health consensus criteria. 34 Peripheral blood sorted (CD3 and CD33) and BM chimerism were assessed at days 30, 90, 180 and 360 by PCR. Disease restaging occurred on days 30, 90, 180 and 360, as well as at 18 months, and 2 years.
Statistical analysis
Baseline characteristics were summarized. OS and PFS were estimated from date of transplantation using the Kaplan-Meier method; death or relapse was considered an event in the estimation of PFS. Survival curves were compared using the log-rank test. Accounting for competing risk events, cumulative incidence of primary disease c % Blasts in BM preceding HCT for those with active disease at the time of HCT. Four cases had 0% BM blasts on most recent BM preceding HCT, but had active disease: one with biopsy proven active leukemia cutis; one with 45% and increasing peripheral blood blasts, confirmed by flow cytometry; and two with persistent clonal cytogenetic abnormalities. d aGVHD prophylaxis: Six total patients originally treated with TAC/MTX as prophylaxis did not complete full intended course of MTX due to severe mucositis; in these cases, MMF was then added as substitute prophylaxis. e Four cases with MMUD did not receive ATG: one had A Ag mismatch and received Campath; all others received no additional GVHD prophylaxis (included DRB1, C and DQ mismatch, respectively).
relapse and NRM was calculated. 35 For the outcomes of OS and PFS, the relationships between these outcomes and all baseline variables were examined by first applying the univariable analysis. Cox proportional hazard modeling was used with baseline variables as covariates. For cumulative incidence of relapse or NRM, a subdistribution hazards regression model by the method of Fine and Gray was used for univariable and multivariable analysis. 36 Those variables with P-value p0.2 in univariable analysis were selected for construction of the multivariable model. Backward selection procedure with a P cutoff of 0.1 was used. Separate multivariable analyses were conducted to examine pre-and post-HCT variables. Analysis of number of induction cycles was restricted to those in the first CR (CR1) at the time of HCT. The analysis of % BM blasts was restricted to those with active disease (relapse (REL), primary induction failure (PIF)) at HCT. The use of ATG, day 90 peripheral blood CD3 and CD33 chimerism, and time in the first CR were not considered in the multivariable models on account of missing observations. As there was only one subject with 0 cycles of induction therapy (untreated), and also only one with TAC/SIR as aGVHD prophylaxis, these subjects were excluded from univariable and multivariable analyses. The impact of subject age on outcomes was examined by several methods. First, age was examined in univariable and multivariable modeling for all major outcomes, including OS, PFS, relapse and NRM. Next, separate multivariable analysis was performed examining age, cytogenetic risk group, and primary vs secondary disease to investigate the influence of age, independent of potential associations with adverse cytogenetics or secondary AML. Finally, OS and PFS curves were stratified by age groups in the following samples: all patients, restricted to CR1, primary disease, secondary disease and by each cytogenetic risk group. Comparisons were made with the log-rank test.
Results
In all, 100 consecutive adults with AML were conditioned with t-i.v. BU/Flu at the center from 2004 to 2008. Remission status included: CR1 (n ¼ 49), CR2 (n ¼ 25), relapsed disease (n ¼ 9), PIF (n ¼ 16) and untreated (n ¼ 1). The PIF group had a median age of 59.5 (range 29-68) years, had one to three cycles of induction chemotherapy, and had a median of 11% blasts (range 0-80%) in the final BM biopsy preceding HCT; one patient with 0% blasts had received three sequential cycles of induction chemotherapy for persistent disease, had not recovered from pancytopenia and had persistent cytogenetic abnormalities before HCT.
Median actual AUC after the first dose was 5113 mM min (range 2796-9355) for the 5300 mM min target subgroup and 4244 mM min (range 2830-5347) for the 3500 mM min target subgroup. Daily BU doses were adjusted accordingly to achieve the target AUC averaged over 4 days. Median total BU dose required to achieve the target AUC was 520 mg/m 2 (range 370-974) in the 5300 mM/L min group and 418 mg/m 2 (range 254-470) in the 3500 mM/L min group. The regimen was overall well tolerated and effective in securing engraftment. There were no cases of engraftment failure. In regard to toxicity, there were no cases of seizure within 72 h of last dose of BU. There were no cases of hepatic veno-occlusive disease. There was one cases of idiopathic pneumonia syndrome; this was treated with steroids and etanercept. Maximal liver toxicity (transaminase or bilirubin elevation not due to hepatic veno-occlusive disease or aGVHD) within 100 days post transplant was the following (as per CTC ver 4.0, NCI Cancer Therapy Evaluation Program, 2010): grade 0 (n ¼ 39), grade 1 (n ¼ 38), grade 2 (n ¼ 14), grade 3 (n ¼ 8) and grade 4 (n ¼ 1).
Median time to neutrophil engraftment was 16 days (range 10-28), and median time to platelet engraftment was 12 days (range 6-36) in 98 evaluable cases; in two cases, relapse of AML occurred before achievement of these threshold levels at days 19 and 43, respectively, after transplant. All other patients sustained their graft.
Day-90 BM demonstrated a median of 97% donor chimerism (range 10-100%). Day 90 CD3 compartment (n ¼ 53) in the peripheral blood demonstrated a median of 90% donor chimerism (range 18-100%). Day 90 CD33 compartment (n ¼ 50) in the peripheral blood demonstrated a median of 100% (range 10-100%) donor chimerism. Given the potential impact of ATG treatment on chimerism, we evaluated the relationship between ATG treatment and donor chimerism by w 2 -test. Treatment with ATG was not significantly associated with unsorted BM or CD3 donor chimerism at day 90 (w 2 P ¼ 0.69 and 0.1, respectively). By day 100 after HCT, 82% manifested biopsy confirmed overall grade II-IV aGVHD (grade II, n ¼ 61; grade III, n ¼ 13; and grade IV, n ¼ 8). By date of death or last follow-up, 62% in total manifested any grade cGVHD, and moderate to severe cGVHD occurred in 40% (mild, n ¼ 22; moderate, n ¼ 27; and severe, n ¼ 13).
NRM was 3% at 100 days, and 15% at 1 year (Figure 1 ). Age and remission status at time of HCT were not associated with NRM. In the multivariable analysis of pre-HCT variables (Table 2) 
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Relapse Non-relapse mortality Figure 1 Cumulative incidence of relapse and nonrelapse mortality.
with MMF here is consistent with excess mortality from severe GVHD as previously published. 37 In the multivariable analysis of post-HCT variables, maximal grade of aGVHD (grade III-IV vs 0-I) was significantly associated with worse NRM (HR 5.71, 95% CI: 1.2-27.8; P ¼ 0.03) ( Table 3) .
The 3-year cumulative incidence of disease relapse according to remission status at HCT was the following: CR1 30.6%, CR2 41.7%, REL 55.6% and PIF 58.6%. On univariate analysis, relapse significantly differed according to remission status at HCT. In multivariate analysis of pre-HCT factors, remission status and patient age were not significant predictors of relapse. In the multivariable analysis of post-HCT variables, day-90 BM chimerism X90% was a significant predictor of relapse (HR 0.18, 95% CI: 0.06-0.5; P ¼ 0.001) analysis (Table 3) . Donor CD3 chimerism was not significantly associated with relapse.
With a median follow-up of 17 months (range 1.5-53), the median OS for all subjects is 21 months (95% CI: 11-not reached). Point estimates for OS are 59% (95% CI: 48-67%) at 1 year, and 49% (95% CI: 39-59%) at 2 years. Causes of death included relapse (n ¼ 29), infection (n ¼ 7), respiratory failure (n ¼ 5), refractory aGVHD (n ¼ 4), refractory cGVHD (n ¼ 1), multiorgan failure (n ¼ 2), post transplant lymphoproliferative disease (n ¼ 1) and unknown (n ¼ 3). Survival significantly differed according to remission status at the time of transplant, consistent with the increased hazard for relapse death with advanced remission status ( Figure 2) ; OS for those with primary AML in CR1 was 66% (95% CI: 46-80%) at 1 year and 62% (95% CI: 42-77%) at 2 years. OS did not significantly differ when stratified by cytogenetic risk group, both in the overall sample, as well as when only restricted to those in CR1 (Figure 2 ). On Cox proportional hazard multivariable modeling, relapsed disease at time of transplant (HR 10.6 (95% CI: 1.9-60), P ¼ 0.007) was a significant negative predictor of OS (Table 2 ). In the multivariable model of post-HCT variables, moderate/severe cGVHD (HR 0.28, 95% CI: 0.1-0.76; P ¼ 0.01) and BM chimerism X90% (HR 0.25, 95% CI: 0.076-0.79; P ¼ 0.018) were significant predictors of OS (Table 3) . Those with o90% BM chimerism suffered poor outcomes, with a median OS of 7.8 months (95% CI: 5.1-not reached) and PFS of 3.6 months (95% CI: 2.2-6.8), whereas median OS and PFS were not reached in the X90% BM chimerism group, P ¼ 0.04 and o0.0001 for the comparisons, respectively. Donor CD3 chimerism was not significantly associated with OS.
In univariable and multivariable analyses for all major outcomes, including OS, PFS, relapse and NRM, age was not a significant predictor. In separate multivariable analysis examining only age, cytogenetic risk group, and primary vs secondary disease, age did not significantly impact OS or PFS. OS and PFS survival curves stratified by age groups for all patients, CR1 only, primary and secondary disease, as well as for each cytogenetic risk group were not significantly different by log-rank comparison. Strikingly, those in CR1 age 460 years (Figure 2c ) achieved a 1-and 2-year OS of 60% (95% CI: 12.6-88.2%); however, this observation is circumscribed by the limited Values for each represent hazard ratio for outcome (95% confidence interval), P-value. Figure 3) ; PFS for those with primary AML in CR1 was 56.7% (95% CI: 37.3-72.1) at 1 year, and 53% (95% CI: 33.7-69%) at 2 years. There were no significant differences in PFS among subgroups when stratified by cytogenetic risk, both in the overall sample and in only considering those in CR1. On univariate analysis of pre-HCT variables, remission status was a significant predictor of PFS, with relapsed disease HR of 3.7 (95% CI: 1.6-8.2, P ¼ 0.0016) ( Table 2 ). This did not remain significant on multivariable analysis. In the analysis of post-HCT variables, day-90 BM chimerism of X90% predicted PFS (Table 3) ; on multivariable modeling, HR was 0.18 (95% CI: 0.08-0.5; P ¼ 0.0002). Donor CD3 chimerism was not significantly associated with PFS.
Discussion
Reduced toxicity conditioning regimens may extend benefits of HCT for AML to older adults. Several investigators have reported outcomes in the treatment of MDS and AML using conditioning regimens that range in intensity from purely nonmyeloablative to reduced-or intermediateintensity regimens using ablative doses of BU, but suffer from small sample size and heterogeneity in many important variables, including the inclusion of both MDS and AML. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We here report the results of the largest series of exclusively AML in adults treated with t-i.v. BU/ Flu with allogeneic HCT.
The approach of pharmacokinetic-targeted BU and substitution of fludarabine for CY allowed for low nonhematological toxicity. Despite the age of these subjects (median age 48 years, and 22 subjects over the age of 60 years), NRM was low. [38] [39] [40] The NRM realized with t-i.v. BU/Flu compares favorably with other reduced or intermediate-intensity regimens, where the published 1-year NRM ranges from 14% in the nonmyeloablative regimen of 2 Gy TBI/Flu 5 to as high as 50-66% with other reduced to intermediate-intensity regimens. 10, 15 In keeping with observations from other series, NRM significantly differed according to the maximal aGVHD grade reached. 11, 12 Importantly, grade II-IV aGVHD in this series is clearly in excess of that reported in other series, which is likely explained by a greater proportion of mismatched unrelated donors, and the frequent use of upper endoscopy to investigate early symptoms of gastrointestinal GVHD. 41 More effective prevention of aGVHD in this series may have resulted in even lower NRM. Importantly, this regimen was well tolerated, with no adverse impact of advanced age on NRM.
The low NRM is complemented by effective disease control. The cumulative incidence of relapse for those in CR1 at HCT was 30.6%. This compares favorably with major randomized trials and meta-analyses with exclusively AML in CR1 treated with myeloablative conditioning, where relapse reaches 29-36% by 4-7 years. 1, 43, 44 This is further bolstered by the fact that the majority of patients in CR1 in this series were at high risk for chemotherapy failure, given WBC at presentation 4100, adverse risk cytogenetics, 41 cycle of induction therapy required to achieve CR, and secondary disease. The regimen has remarkable activity in those with secondary AML in CR1, as well with 1 and 2 year PFS of 58 and 53%, respectively. These results are striking, given the poor outcomes previously reported: In an analysis of 56 patients with secondary AML treated with CY/TBI, BU/CY or targeted BU/CY, Witherspoon et al. 45 reported disease-free survival of only 20% at 1 year, and 9% at 5 years.
Predictors of OS and PFS identified in this series are supported by related investigation; Shimoni and de Lima have similarly demonstrated remission status at time of transplant to be a significant predictor of OS.
11, 13 Valcarcel et al. 12 has also demonstrated the beneficial impact of moderate to severe cGVHD on OS in the setting of reduced intensity conditioning, which is consistent with a broader literature demonstrating the antileukemic effect associated with the occurrence of GVHD after HCT. 42, 46 Day-90 BM chimerism as a favorable predictor of OS, PFS and relapse is substantiated by an extensive literature that demonstrates the prognostic importance of both unsorted BM or peripheral blood donor chimerism, [47] [48] [49] [50] as well as peripheral blood T-and natural killer-cell chimerism. 51 AML relapse after HCT remains a challenge. Further efforts to mitigate post-HCT relapse could include the following: As conditioning regimen intensity is an important mediator of effective disease control, 6, 11, 20, 52 investigation directed at examining increased intensity within reduced-intensity conditioning regimens may be warranted; the optimal intensity to provide best disease control and yet also spare treatment-related toxicity and mortality remains to be defined. As remission status at HCT is an important factor in post-HCT outcome, novel approaches at more effective induction therapy may allow for more effective long-term disease control. Alternatively, maintenance antileukemic therapy after HCT may be able to consolidate responses after HCT. 53 Efforts at immunosuppression taper to augment graft vs malignancy activity have not proved beneficial to date. 20 However, more rigorous study of immunosuppressive management after HCT is needed. Finally, donor lymphocyte infusion either as preemptive therapy after HCT or upon relapse after HCT offers promise, but its application is limited by its associated burden of severe graft vs host disease.
15,54
Conflict of interest C Anasetti and J Perkins have received research support from PDL Biopharma for conducting research on targeted BU conditioning. The remaining authors declare no conflict of interest. 
